ARVO

Thumbs Up at ARVO for Diaton Tonometer - New Through Eyelid Glaucoma Test Clinical Study Presented, Results as Accurate as Gold Standard

Unique Transpalpebral and Transcleral Diaton Tonometer is presented at The Association for Research in Vision and Ophthalmology ARVO by BiCOM Inc. New Clinical Study presented "Accuracy of Transpalpebral Tonometer Diaton Compared to Goldmann Applanation Tonometer in Normal and Glaucomatous...

Novadaq's OPTTX System Data Presented at ARVO

Visual Acuity Reported to Remain Stable or Improve in 86% at Six Months TORONTO, May 9 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time imaging and image guidance systems for use in the operating room, today announced that independent data was presente...

ARVO 2009 award recipients

...pients. Five individuals will be recognized at the arvo Annual Meeting, May 3-7 in Fort Lauderdale, Fla. ...ield will present the Proctor Award Lecture at the arvo Annual Meeting this May. The Friedenwald Award... will present the Friedenwald Award Lecture at the arvo Annual Meeting this May. The Mildred Weisenfe...

ARVO announces inaugural class of Fellows

...gural class of distinguished Fellows. The title of arvo Fellow recognizes members for their accomplishment...igorous point system. By accepting this honor, arvo anticipates that Fellows will continue to serve as...ize current members and inspire future ones," said arvo President, Todd P Margolis MD PhD. The...

Young eye researchers receive prestigious ARVO-AFER/Merck award

...ssible by a generous grant from Merck & Co. to the arvo Foundation for Eye Research recognizes outstandin...50 scientists have since received the award. The arvo Foundation for Eye Research will recognize the 2009 IORA recipients in conjunction with the arvo 2009 Annual Meeting, which takes place in Fort Lau...

Conference report highlights new research into drug delivery to treat eye disease

...very to the posterior segment of the eye and includes the findings of and opinions of more than 30 top ophthalmic researchers, brought together by the arvo Foundation for Eye Research. The article in the November issue of Investigative Opthalmology & Visual Science defines the current research and the f...

ARVO Foundation and Merck to provide prestigious global ophthalmic research award

... Rockville, MD -- The arvo Foundation for Eye Research (AFER) and Merck & Co....nts' travel expenses and registration fees for the arvo Annual Meeting, which takes place in Fort Lauderda... each April/May. "Merck is proud to support the arvo Foundation for Eye Research by continuing to spons...

ARVO in Medical Technology

Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting

ATLANTA, May 4 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first ...

Dr. Gabriel Sosne to Present New TB4 Data at 2007 ARVO Meeting

BETHESDA, Md.--(BUSINESS WIRE)--May 7, 2007 - REGENERX BIOPHARMACEUTICALS' (AMEX: RGN), www.regenerx.com - Dr. Gabriel Sosne will be speaking at the 2007 Association for Research in Vision and Ophthalmology (ARVO) meeting in Ft. Lauderdale, Florida on May 9th to discuss TB4's ability to inhibit cor...

VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 9, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive results from several studies evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD) and diabetic macular edema (DME). These findi...

GenVec Presents Research on New Ad35 Adenovector at ARVO

GAITHERSBURG, Md.--(BUSINESS WIRE)--May 10, 2007 - GenVec, Inc. (Nasdaq:GNVC) today announced pre-clinical research demonstrating the ability of the Company's new adenovector, Ad35, to induce and sustain protein production in the eye. Lisa L. Wei, Ph.D., GenVec's Director of Pre-Clinical Research, ...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

...veloping a protocol for Phase I/II clinical trials in humans to take place over the coming year. Founded in 1928 with 12,000 members currently, arvo is one of the nation's largest organizations for research in vision and ophthalmology. For more information, see www.arvo.org . The Vision Cen...

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting

... Vitrase(R) Solutions after Dilution in Anesthetics Authors: B.A. Aird, J.D. Dahlstrom, G.A. Baklayan, J.A. Gow Abstracts are available on the arvo website at http://www.arvo.org . About ISTA Pharmaceuticals ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's prod...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... may be permanent, and related to the death of photoreceptor cells, the cells responsible for capturing light in the retina. We have presented data at arvo demonstrating that a single intraocular injection of Palomid 529, a drug originally designed as an anti-angiogenic agent, can significantly reduce thi...

ARVO, AOS: Large Study of Lacrisert(R) Dry Eye Insert;

...ealth and quality of life for dry eye sufferers can be meaningfully improved by use of the insert in a relatively short time." A second poster at arvo based on the patient registry study, "Effect of Lacrisert(R) on the Signs and Symptoms of Dry Eye in Contact Lens Wearers" (Wednesday, May 06, 2009, 1...

Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

...udy was provided in a press release made by Sirion on April 15th, 2009. The arvo presentations on fenretinide contain a more detailed analysis of the data o...sis. Identified below are the presentations scheduled for the upcoming arvo meeting. Dose Uniformity of Prednisolone Acetate Ophthalmic Suspensi...

Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

...iting the foregoing, but by way of example, statements contained in this press release concerning prospects related to the presentation of data at the arvo 2008 annual meeting, ISTA initiating further studies on the combination use of Xibrom and Lucentis, and ISTA's goals of bringing a new product to mark...

More>>

ARVO in Biological News

Six previously blind patients detect light, motion, identify objects with retinal prostheses

...A. Roy, G. Fujii, R.J. Greenberg, J. Little, B. Mech, J.D. Weiland, E. de Juan, Jr., "Implanted Intraocular Retinal Prosthesis in Six Blind Subjects," arvo 2005, Retinal Prosthesis I, Monday, May 2, 12:15 p.m. ...

ARVO in Biological Technology

Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3

FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04...

Optherion Announces Presentation at ARVO 2009 Annual Meeting

"A Clinical Study to Identify a Population with Blood-Based Biomarkers for Age-Related Macular Degeneration (AMD)" NEW HAVEN, Conn., April 29 /PRNewswire/ -- Optherion, Inc., a company developing novel molecular diagnostics and treatments for dry and wet Age-related Macular Degeneration (AMD)...

Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO

TAMPA, Fla., April 21 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that preclinical results for two new compounds targeted for the treatment of retinal diseases will be presented during the 2008 Annual Meeting of the ...

First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease

...ids like prednisone, which in turn reduces the serious side-effects associated with those drugs." Dr. Rosenbaum noted that a poster presentation at arvo from a survey of U.S. ophthalmologists and rheumatologists from 27 states, presented by researchers from the Wilmer Eye Institute of Johns Hopkins Uni...

Baltimore LASIK Surgeon Roy Chuck, MD, PhD of the Wilmer Eye Institute at Johns Hopkins Lists with Trusted LASIK Surgeons

...e Alpha Omega Alpha National Medical Honor Society and has also been honored with a Heed Ophthalmic Foundation Fellowship and a National Eye Institute arvo Travel Grant, and National Institutes of Health Research Grants. "I have known and respected Dr. Chuck for over 10 years beginning when he fi...

ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007

...ve results from the MIVI I trial (microplasmin in vitrectomy) at the annual arvo and Euretina congresses The MIVI-I trial was a Phase IIa, open-label, dose...hment, diabetic vitreous hemorrhage and macular hole. Results presented at arvo (the Association of Research in Vision and Ophthalmology) and Euretina cong...